Clorazepate use may prevent alcohol withdrawal convulsions

Area of Science:

• Pharmacology
• Neurology
• Addiction Medicine

Background:

• Alcohol withdrawal syndrome (AWS) can manifest with severe symptoms, including potentially life-threatening seizures.
• Benzodiazepines are commonly used for AWS management, but specific efficacy data for certain agents in seizure prevention is crucial.

Purpose of the Study:

• To evaluate the prophylactic efficacy of clorazepate dipotassium in preventing alcohol withdrawal seizures.
• To assess the overall effectiveness of clorazepate dipotassium in managing signs and symptoms of AWS.

Main Methods:

• Oral administration of clorazepate dipotassium for five-day prophylactic treatment.
• Study conducted on 226 patients admitted to an inpatient alcohol treatment unit.
• Seizure incidence compared against historical and literature-based predictions.

Main Results:

• No patients (0%) experienced withdrawal convulsions during the treatment period.
• Predicted seizure incidence ranged from 3% to 18% (7 to 40 patients) based on historical data.
• Complete absence of seizures suggests significant anticonvulsant activity.

Conclusions:

• Clorazepate dipotassium demonstrated complete efficacy in preventing alcohol withdrawal seizures in this patient cohort.
• The findings support the use of clorazepate dipotassium as an effective agent for managing alcohol withdrawal syndrome and preventing seizures.